Opinion|Videos|August 12, 2024
Dr Parrondo shares Approach to Managing BTKi Treatment-Related Afib
An oncology specialist outlines their general approach to managing treatment-related atrial fibrillation in patients receiving BTK inhibitor therapy, incorporating insights from recent clinical data to inform their management strategies.
Advertisement
Episodes in this series
- Dr Parrondo:What is your general approach in managing treatment-related Afib in patients receiving treatment with BTKi inhibitors? What insights do recent data provide?
- Kaiser RWD -
Krackeler, et al. ASCO 2024. Abs 11158 @54:33 zanubrutinib go away over time. Less cardiac
- What is the role of medications for anticoagulation and rhythm control? Dose reductions/holds?When do you involve cardiology?
- When may alternative therapy be warranted and what is your approach in these scenarios?
Advertisement
Related to this article
Lisaftoclax plus acalabrutinib earned breakthrough therapy status in China for untreated CLL/SLL.
The top 5 OncLive TV videos of the week cover insights in multiple myeloma, HR+ breast cancer, CAR T-cell therapy, CLL, and oral SERDs.
The top 5 OncLive TV videos of the week.
Read a refresh of hematologic cancer FDA and global regulatory news from September 2026.
Advertisement
Advertisement
Trending on OncLive
1
FDA Grants Full Approval to Pembrolizumab for Unresectable/Metastatic TMB-H Solid Tumors
2
HER2+ mCRC Treatment Sequencing Favors Tucatinib Plus Trastuzumab Before T-DXd
3
Polls Reveal Top Picks for Lung Cancer Abstracts of Interest at ESMO 2026
4
Poll Results Highlight Gynecologic Cancer Abstracts of Interest at ESMO 2026
5